Annual Cash & Cash Equivalents
$9.43 M
-$10.56 M-52.82%
December 31, 2023
Summary
- As of March 10, 2025, OCX annual cash & cash equivalents is $9.43 million, with the most recent change of -$10.56 million (-52.82%) on December 31, 2023.
- During the last 3 years, OCX annual cash & cash equivalents has risen by +$2.29 million (+32.05%).
- OCX annual cash & cash equivalents is now -71.37% below its all-time high of $32.95 million, reached on December 31, 2021.
Performance
OCX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$3.36 M
-$5.89 M-63.67%
September 30, 2024
Summary
- As of March 10, 2025, OCX quarterly cash and cash equivalents is $3.36 million, with the most recent change of -$5.89 million (-63.67%) on September 30, 2024.
- Over the past year, OCX quarterly cash and cash equivalents has stayed the same.
- OCX quarterly cash and cash equivalents is now -94.29% below its all-time high of $58.91 million, reached on March 31, 2021.
Performance
OCX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
OCX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -52.8% | 0.0% |
| 3 y3 years | +32.0% | -92.5% |
| 5 y5 years | +17.4% | -92.5% |
OCX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -71.4% | at low | -92.5% | at low |
| 5 y | 5-year | -71.4% | +32.0% | -94.3% | at low |
| alltime | all time | -71.4% | +9238.6% | -94.3% | +1208.6% |
OncoCyte Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $3.36 M(-63.7%) |
| Jun 2024 | - | $9.26 M(+65.9%) |
| Mar 2024 | - | $5.58 M(-40.9%) |
| Dec 2023 | $9.43 M(-52.8%) | $9.43 M(-31.6%) |
| Sep 2023 | - | $13.78 M(-20.6%) |
| Jun 2023 | - | $17.37 M(+47.1%) |
| Mar 2023 | - | $11.80 M(-41.0%) |
| Dec 2022 | $19.99 M(-39.3%) | $19.99 M(-37.6%) |
| Sep 2022 | - | $32.05 M(-28.5%) |
| Jun 2022 | - | $44.84 M(+119.7%) |
| Mar 2022 | - | $20.41 M(-38.0%) |
| Dec 2021 | $32.95 M(+361.3%) | $32.95 M(-24.0%) |
| Sep 2021 | - | $43.34 M(-6.7%) |
| Jun 2021 | - | $46.47 M(-21.1%) |
| Mar 2021 | - | $58.91 M(+724.7%) |
| Dec 2020 | $7.14 M(-67.6%) | $7.14 M(-30.6%) |
| Sep 2020 | - | $10.29 M(-38.7%) |
| Jun 2020 | - | $16.80 M(+1.3%) |
| Mar 2020 | - | $16.58 M(-24.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2019 | $22.07 M(+174.7%) | $22.07 M(+13.5%) |
| Sep 2019 | - | $19.44 M(-45.7%) |
| Jun 2019 | - | $35.83 M(-8.7%) |
| Mar 2019 | - | $39.26 M(+388.6%) |
| Dec 2018 | $8.03 M(+5.7%) | $8.03 M(-25.8%) |
| Sep 2018 | - | $10.82 M(+5.1%) |
| Jun 2018 | - | $10.29 M(-18.4%) |
| Mar 2018 | - | $12.61 M(+65.9%) |
| Dec 2017 | $7.60 M(-25.3%) | $7.60 M(-31.1%) |
| Sep 2017 | - | $11.02 M(+27.5%) |
| Jun 2017 | - | $8.64 M(-23.9%) |
| Mar 2017 | - | $11.35 M(+11.6%) |
| Dec 2016 | $10.17 M(+27.2%) | $10.17 M(-19.7%) |
| Sep 2016 | - | $12.67 M(+216.8%) |
| Jun 2016 | - | $4.00 M(-31.7%) |
| Mar 2016 | - | $5.86 M(-26.8%) |
| Dec 2015 | $8.00 M(+3011.3%) | $8.00 M(-15.0%) |
| Sep 2015 | - | $9.41 M(+3561.5%) |
| Dec 2014 | $257.00 K(+154.5%) | $257.00 K |
| Dec 2013 | $101.00 K | - |
FAQ
- What is OncoCyte annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for OncoCyte?
- What is OncoCyte annual cash & cash equivalents year-on-year change?
- What is OncoCyte quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for OncoCyte?
- What is OncoCyte quarterly cash and cash equivalents year-on-year change?
What is OncoCyte annual cash & cash equivalents?
The current annual cash & cash equivalents of OCX is $9.43 M
What is the all time high annual cash & cash equivalents for OncoCyte?
OncoCyte all-time high annual cash & cash equivalents is $32.95 M
What is OncoCyte annual cash & cash equivalents year-on-year change?
Over the past year, OCX annual cash & cash equivalents has changed by -$10.56 M (-52.82%)
What is OncoCyte quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of OCX is $3.36 M
What is the all time high quarterly cash and cash equivalents for OncoCyte?
OncoCyte all-time high quarterly cash and cash equivalents is $58.91 M
What is OncoCyte quarterly cash and cash equivalents year-on-year change?
Over the past year, OCX quarterly cash and cash equivalents has changed by $0.00 (0.00%)